FMP
Nanobiotix S.A.
NBTX
NASDAQ
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
3.34 USD
0.031 (0.928%)
2024 Q2
2023 Q4
2023 Q2
2022 Q4
9.29M
32.91M
3.29M
1.72M
0
0
0
754k
9.29M
32.91M
3.29M
969.5k
32.94M
34.32M
28.66M
23.49M
21.99M
20.59M
17.8M
15.53M
10.83M
11.19M
10.86M
7.98M
0
0
0
0
0
0
0
0
121k
2.55M
-6k
25k
-23.65M
-1.41M
-25.37M
-24.25M
1.92M
-10.07M
-2.73M
-4.93M
-21.73M
-11.48M
-28.1M
-33.72M
144k
117k
3k
-3.03M
-21.87M
-11.6M
-28.1M
-30.68M
-0.46
-0.3
-0.8
-0.88
-0.46
-0.31
-0.8
-0.88
47.12M
37.99M
35.04M
34.85M
47.12M
38.82M
35.04M
34.85M
-23.24M
1.41M
-24.64M
-10.26M
2024 Q2
2023 Q4
2023 Q2
2022 Q4
-336.45M
-39.7M
-28.1M
-57.04M
-21.87M
-11.6M
-28.1M
-30.68M
0
0
0
0
0
0
0
0
-68.13M
-336.45M
-39.7M
-28.1M
268.32M
-296.75M
-11.6M
28.94M
2024 Q2
2023 Q4
2023 Q2
2022 Q4
5.54M
5.75M
6.25M
6.48M
287k
274k
741k
754k
-489k
-5k
-324k
-14k
5.74M
5.48M
5.83M
5.74M
2024 Q2
2023 Q4
2023 Q2
2022 Q4
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in EUR.